<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03162237</url>
  </required_header>
  <id_info>
    <org_study_id>CellTransplant&amp;GeneTherapy2013</org_study_id>
    <nct_id>NCT03162237</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study of Islets Xenotransplantation</brief_title>
  <official_title>Investigation of Safety and Efficacy Study of Islets Xenotransplantation for Patients With Type 1 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wei Wang,MD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hunan Xeno-life Science Ltd</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Central South University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The neonatal pig islets will be used as donor culturing with our modified culture medium. At
      the same time the autologous T regulatory cells will be used to induce specific immune
      tolerance for porcine islets grafts combined the costimulation of T cell activation channel
      blockers. The treatment for type 1 diabetes will be evaluated the efficacy and safety.
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date>July 2013</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Blood glucose</measure>
    <time_frame>1 year</time_frame>
    <description>Before and after transplantation the patient will be tested the blood glucose. If the blood glucose within 24 hours is stable and no occurrence of diabetic ketoacidosis and hypoglycemia.Thirty percent reduction of exogenous insulin requirement will be considered as effective.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Porcine C-peptide</measure>
    <time_frame>1 years</time_frame>
    <description>The patient will be detected the porcine C-peptide levels after transplantion every three months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemoglobin A1c</measure>
    <time_frame>1 years</time_frame>
    <description>After transplantation the patient will be checked hemoglobin A1c every month.The level of HbA1c less than 6.5% was considered as effective.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AST</measure>
    <time_frame>1 years</time_frame>
    <description>AST will be tested every three months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ALT</measure>
    <time_frame>1 years</time_frame>
    <description>ALT will be tested every three months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Scr</measure>
    <time_frame>1 years</time_frame>
    <description>Scr will be tested every three months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BUN</measure>
    <time_frame>1 years</time_frame>
    <description>BUN will be tested every three months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ultrasonic examination for liver</measure>
    <time_frame>1 years</time_frame>
    <description>Ultrasonic examination will be used for the recipient's liver before transplantation and every three month post transplantation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MRI for liver</measure>
    <time_frame>1 years</time_frame>
    <description>MRI will be used for liver before transplantaion and every three month post transplantation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Virus detection</measure>
    <time_frame>2 years</time_frame>
    <description>The recipient's serum and peripheral blood monouclear cells (PBMC) will be collected for virus detection every six months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immune cells detection</measure>
    <time_frame>1 years</time_frame>
    <description>The recipient's peripheral blood monouclear cells (PBMC) and the serum will be collected for immune cell's analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cytokine detection</measure>
    <time_frame>1 years</time_frame>
    <description>The recipient's peripheral blood monouclear cells (PBMC) and the serum will be collected cytokine beads array (CBA) test.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Type 1 Diabetes</condition>
  <arm_group>
    <arm_group_label>Porcine islets and autologous treg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Porcine islets:10000 islet equivalent（IEQ）/Kg; Treg:2x10^6/Kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AutologousTreg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Autologous Treg:2x10^6/Kg</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Porcine islets</intervention_name>
    <description>Porcine islets: 10000IEQ/Kg;
Tacrolimus: 0.087mg/kg, Bid;
mycophemo—latemofetil (MMF): 1g x 2/d;
NULOJIX(belatacept): Day 1 (prior to transplantation), Day 5, Week 2, Week 4, Week 8, Week 12 10mg/kg</description>
    <arm_group_label>Porcine islets and autologous treg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Autologous Treg</intervention_name>
    <description>Autologous Treg: 2x10^6/Kg</description>
    <arm_group_label>Porcine islets and autologous treg</arm_group_label>
    <arm_group_label>AutologousTreg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female patients age 18 to 40 years of age;

          -  Type 1 diabetes mellitus for at least 5 years;

          -  Body weight 40 to 60kg;

          -  Ability to provide written informed consent;

          -  Manifest signs and symptoms that are severe enough to be incapacitating;

          -  Patients with poor diabetes control (HbA1c &gt; 9% );

          -  Patients have diabetes ketoacidosis or hypoglycemia more than once

        Exclusion Criteria:

          -  Age &lt; 18 years or &gt; 60 years;

          -  Diabetes history &lt; 5 years;

          -  Body weight &gt; 80 kg;

          -  Exogenous insulin requirement &gt; 1 unit/kg/day;

          -  Blood test: hemoglobin male &lt; 90g/l, female &lt; 90 g/l) or Wbc &lt;3×109/L, lymphocyte
             &lt;1.5×10^9/L; or platelet &lt; 80×10^9/L; activated- partial-thromboplastin-time （APTT） &gt;
             normal value (31-43s)10s;

          -  Liver dysfunction;

          -  Kidney dysfunction;

          -  Cardiopulmonary dysfunction;

          -  Combined mental illness, cancer, infection, severe trauma, pancreatitis, surgery or
             other stress situations for patients; gastric ulcer patients, any bleeding disorders,
             tuberculosis infection and active infection including hepatitis B, hepatitis C, HIV,
             or John Cunningham virus;

          -  Serological detection Epstein-Barr virus (EBV) or Cytomegalovirus (CMV)negative;

          -  Patient have taken immunosuppressant in recent one year With high incidence of
             malignancy in three generation;

          -  Women not using effective contraception of childbearing age, or planning pregnancy in
             nearly two years or being pregnant or lactating;

          -  Patients can not comply with the research program to complete the diagnosis and
             treatment;

          -  Patients not be passed by Ethics committee
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wei Wang, PHD,MD</last_name>
    <role>Study Chair</role>
    <affiliation>Cell transplantation and gene therapy, the 3rd Xiangya hospital of Central South University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cell Transplantation and Gene Therapy Institute</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410013</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 29, 2014</study_first_submitted>
  <study_first_submitted_qc>May 19, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 22, 2017</study_first_posted>
  <last_update_submitted>May 19, 2017</last_update_submitted>
  <last_update_submitted_qc>May 19, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 22, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Central South University</investigator_affiliation>
    <investigator_full_name>Wei Wang,MD</investigator_full_name>
    <investigator_title>Director of Cell Transplantation and Gene Therapy Institute</investigator_title>
  </responsible_party>
  <keyword>Type1 diabetes</keyword>
  <keyword>porcine islets</keyword>
  <keyword>treg cells</keyword>
  <keyword>immunosuppress</keyword>
  <keyword>xenotransplantation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

